Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Bowen-Yacyshyn

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Opinion in Molecular Therapeutics|November 21, 2001
The clinical experience of antisense therapy to ICAM-1 in Crohn's diseaseB Yacyshyn, M B Bowen-Yacyshyn, W Shanahan
Human Immunology|August 10, 1999
Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitisB Yacyshyn, W Maksymowych, M B Bowen-Yacyshyn
Digestive Diseases and Sciences|December 1, 1996
Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeabilityB Yacyshyn, J Meddings, D Sadowski, et al.
Scandinavian Journal of Immunology|April 1, 1996
Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytesB R Yacyshyn, M B Bowen-Yacyshyn, L M Pilarski
Gastroenterology|June 3, 1998
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|May 1, 1992
Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigenG D MacLean, M B Bowen-Yacyshyn, J Samuel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Opinion in Molecular Therapeutics|November 21, 2001
The clinical experience of antisense therapy to ICAM-1 in Crohn's diseaseB Yacyshyn, M B Bowen-Yacyshyn, W Shanahan
Human Immunology|August 10, 1999
Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitisB Yacyshyn, W Maksymowych, M B Bowen-Yacyshyn
Digestive Diseases and Sciences|December 1, 1996
Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeabilityB Yacyshyn, J Meddings, D Sadowski, et al.
Scandinavian Journal of Immunology|April 1, 1996
Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytesB R Yacyshyn, M B Bowen-Yacyshyn, L M Pilarski
Gastroenterology|June 3, 1998
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|May 1, 1992
Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigenG D MacLean, M B Bowen-Yacyshyn, J Samuel, et al.
Pageof 1